EXAGEN INC

Exagen (XGN) slips in a quiet downtrend—no earnings, no partnership, just routine insider activity. With a 200‑day MA at $4.94 and a 52‑week high of $12.23, investors see a speculative bubble, not a solid play.

Exagen’s shares slump amid weak revenue and low volume—why the autoimmune diagnostics company struggles and what investors need to see to regain confidence.